Vigorplus is applied across two distinct therapeutic domains where additional symptomatic support is needed, primarily addressing conditions linked to organ-specific functional stress. The medication is used for the symptomatic management of Erectile Dysfunction (ED) and the chronic context of Pulmonary Arterial Hypertension (PAH).

Functional Support for Vascular Erection Impairment

Vigorplus is commonly used in conditions presenting with recurrent or episodic manifestations of ED, specifically the inability to achieve or maintain the necessary physical response for satisfactory sexual performance. This intervention may assist with improving functional stability and may help patients cope more steadily with episodes of discomfort that interfere with routine activities.

“The medication may assist with maintaining functional stability by supporting the patient during difficult episodes of symptomatic vascular impairment.”

Quick Fact: Symptomatic Support

Focus Area	Symptom Cluster Managed	Core Benefit
Andrology	Vascular Erection Impairment	Supports functional stability

---

Management of Cardiopulmonary Vascular Limitation

The medication is also applied in clinical settings that involve chronic, systemic conditions like PAH, where it is used for managing symptom clusters that create noticeable physiological strain, such as breathlessness on exertion and fatigue. Vigorplus may contribute to easing the overall symptom load and generally may assist with supporting exercise capacity in conditions marked by increased physiological stress.

Regulatory References

1. NIH MedlinePlus overview

Vigorplus (Sildenafil) eligibility is strictly defined by regulatory documents, classifying populations for permitted, restricted, or prohibited use.

Populations for Whom Use is Contraindicated

Use is prohibited for patients taking any form of organic nitrates or nitric oxide donors (e.g., nitroglycerin), or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat). The medicine is also contraindicated in patients with severe hepatic impairment (Child-Pugh Class C), a recent history of stroke or myocardial infarction, hypotension (low blood pressure <90/50 mmHg), or known hereditary degenerative retinal disorders.

Age- and Condition-Based Eligibility

For the Erectile Dysfunction indication, use is not indicated for individuals under 18 years of age. Older adults (65 years and older) or those with severe renal impairment may require special dose consideration due to reduced drug clearance. Use requires caution in patients with anatomical penis deformation (e.g., Peyronie’s disease) or conditions predisposing to priapism. Use during pregnancy and lactation is generally considered conditional, with limited available human data.

Vigorplus Interactions with other medicines and products

The interaction profile for Vigorplus (Sildenafil) is formally documented in regulatory labeling across distinct categories of medicinal products and substances.

Absolute Contraindications

Co-administration is strictly prohibited with Nitrates (in any form) and Guanylate Cyclase Stimulators (e.g., Riociguat). This is documented as an absolute contraindication due to the severe pharmacodynamic risk of life-threatening symptomatic hypotension.

Pharmacokinetic Interactions

The clearance of Vigorplus is predominantly mediated by the CYP3A4 enzyme. Co-administration with potent CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole) is documented to significantly reduce Sildenafil clearance, leading to a substantial increase in systemic plasma exposure (AUC). Conversely, CYP3A4 inducers (e.g., Rifampicin) are documented to decrease exposure. When co-administered with a potent inhibitor such as Ritonavir, the regulatory label imposes a formal restriction on the maximum permissible Sildenafil dosage.

Pharmacodynamic Effects and Administration Constraints

Vigorplus is documented to have an additive blood pressure lowering effect when co-administered with Alpha-Blockers. Regulatory documentation specifies a timing constraint: the patient must be hemodynamically stable on the alpha-blocker therapy before Vigorplus initiation. Additionally, a high-fat meal is documented to reduce the rate of absorption, delaying the time to maximum concentration (Tmax). Clearance reduction observed in severe hepatic or renal impairment is officially noted to amplify exposure risk when interacting agents are present.

Selective Enzyme Inhibition: The PDE5 Target

Vigorplus works by highly selective competitive inhibition of the Phosphodiesterase type 5 ( PDE5) enzyme. This molecular action prevents the rapid degradation of a crucial cellular messenger, cyclic Guanosine Monophosphate ( cGMP), which is necessary for smooth muscle relaxation.

---

Amplifying the Nitric Oxide/ cGMP Cascade

The drug acts as a signal potentiator within the natural Nitric Oxide ( NO)/ cGMP pathway. It requires the initial release of NO to begin cGMP synthesis, then sustains the signal by protecting the cGMP molecule, allowing the vasodilatory sequence to be prolonged.

---

Physiological Effect: Reduction in Vascular Resistance

Sustained cGMP levels activate a cascade that relaxes the vascular smooth muscle lining the blood vessel walls. This targeted vasodilation is the mechanism's functional consequence, leading to a localized reduction in vascular resistance and resulting in increased blood flow capacity in the target area.

How Vigorplus is Used: Official Administration Guidelines

Administration of Vigorplus (Sildenafil) is governed by two distinct established protocols based on the specific condition being addressed. These official instructions determine the appropriate route, strength, frequency, and timing of use.

---

Administration Protocol for Vascular Erection Impairment

This regimen is defined by as-needed use, utilizing oral tablets in strengths of 25 mg, 50 mg, or 100 mg. The typical starting dose is 50 mg, and the maximum single dose is 100 mg, permitted once per day. The dose must be taken orally between 30 minutes and 4 hours prior to activity. Taking the tablet with food may delay the onset of activity. A lower 25 mg starting dose should be considered for older adults (age 65 and over) and patients with severe hepatic or renal impairment.

---

Administration Protocol for Cardiopulmonary Vascular Limitation

This is a scheduled, long-term regimen involving multiple forms. The official routes include oral administration via a 20 mg tablet or oral suspension, and intravenous (IV) injection (10 mg) reserved for patients temporarily unable to take oral medication. The standard oral dose is 20 mg, taken three times a day (TID), with doses spaced 4 to 6 hours apart. Dosing may be taken with or without food. The oral suspension requires reconstitution with a specific volume of water, and pediatric dosing is based on weight.

Evidence for use in Erectile Dysfunction

The research into Vigorplus for managing vascular erection impairment was conducted through numerous short-term randomized controlled trials (RCTs). These studies primarily observed outcomes related to physical discomfort and functional stability, focusing on measures like the success rate of sexual intercourse attempts. Studies reported patterns observed in functional measures, though results apply only to the specific populations studied, as some early trials included patients whose condition was less severe than what is often seen in general clinical practice.

Evidence for use in Pulmonary Arterial Hypertension

The research for Vigorplus in the chronic context of Pulmonary Arterial Hypertension (PAH) is supported by key multi-center RCTs. These trials monitored outcomes related to physiological strain, primarily evaluating changes in exercise capacity (6-minute walk distance) and tracking clinical worsening. While short-term findings are described, long-term effects on mortality are still emerging across systematic reviews, indicating certainty remains low regarding this specific outcome.

Long-term Studies and Research in Specific Patient Groups

While pivotal RCTs typically lasted a few weeks, open-label extension studies provided observational data on sustained use over time. Research also explored use in specific adult subgroups for ED, such as men with diabetes or those post-prostatectomy. For PAH, research was evaluated in pediatric patients, but long-term observational data was associated with findings that were considered in the evidence for this population.

Areas of Research Uncertainty

The evidence landscape contains clear limitations. Sample sizes were modest in some of the subgroup analyses, meaning results apply only to the populations studied and may not generalize broadly. Furthermore, evidence quality varies across studies, and comparative evidence against other treatment options is sometimes lacking. The research provides context but does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References

1. Label: SILDENAFIL tablet (20 mg PAH-specific labeling and research context)

Common questions about Vigorplus (FAQ)

Q: Is Vigorplus the same kind of medicine as other drugs that treat the same condition?

A: Vigorplus contains Sildenafil, which is classified as a selective Phosphodiesterase type 5 (PDE5) inhibitor. This pharmacological classification means the drug works by a targeted mechanism to modulate the vascular system.

Regulatory information states that other medicines used to treat the same conditions may belong to this same class but contain different active ingredients.

Q: What does it mean that Vigorplus is a 'controlled substance'?

A: Vigorplus is an FDA-approved, prescription-only medication. According to official classification, the active ingredient (Sildenafil) is not defined as a controlled substance under the U.S. Controlled Substances Act.

Its classification confirms its status as a prescription-only medication not listed under the U.S. Controlled Substances Act.

Q: How long does the main effect of Vigorplus usually last?

A: The time the effect lasts can vary between individuals. According to official pharmacokinetic data, the main active compound in Vigorplus has an elimination half-life of about four hours.

For the as-needed regimen, studies indicate that effects can be observed for up to four hours. The intensity of the reported response is often diminished after two hours.

Q: What happens if I forget to take Vigorplus one day?

A: For patients on the scheduled, long-term PAH regimen, regulatory guidance advises how to manage a missed dose. If you forget to take a dose, you should take it as soon as you remember, unless it is almost time for your next scheduled dose.

Regulatory documents indicate that if this occurs, the patient should skip the missed dose and continue with the next scheduled dose. Taking a double dose is generally advised against.

Q: Is there a different name for Vigorplus in other countries?

A: Yes, the active ingredient in Vigorplus is Sildenafil, and this compound is marketed under different brand names globally. These names, such as Viagra and Revatio, depend on the country of sale and the specific medical condition being treated.

Q: Do the side effects of Vigorplus usually go away after the first week?

A: Official product information suggests that some common side effects, such as flushing or headache, may be self-limited and are reported as resolving.

For patients taking the long-term PAH regimen, the frequency and intensity of headaches were reported to decrease after the first week of use.

Q: Is Vigorplus safe to use for people over 70?

A: Regulatory information addresses the use of Vigorplus in older adults (age 65 and over). Official documents state that a lower starting dose is often formally considered for this population.

This is due to the potential for reduced drug clearance, which can increase the exposure to the medicine in the body.

Q: Can women who are planning pregnancy use Vigorplus?

A: Regulatory documents state that data regarding Sildenafil use during human pregnancy is limited.

The label advises that the medicine should be used during pregnancy only if the potential benefit is believed to justify the potential risk. The consideration of risks and benefits is reserved for the prescribing professional.

Q: Is Vigorplus safe for people who have kidney issues?

A: Regulatory documents address the use of Vigorplus in people with kidney issues. Official dosing protocols state that a lower starting dose is often recommended for people with severe renal impairment.

This adjustment is necessary because reduced kidney function can decrease the body's ability to clear the drug.

Q: Can I stop taking Vigorplus suddenly if I feel better?

A: Official regulatory documents generally do not list withdrawal symptoms associated with Vigorplus use. Clinical trial reports show that some patients discontinued treatment due to adverse events or lack of therapeutic effect.

Consultation with a healthcare provider is generally recommended prior to ceasing any long-term treatment regimen.

Q: Does Vigorplus interact with over-the-counter pain relievers like ibuprofen?

A: Official drug labels typically do not report a direct interaction between the active ingredient in Vigorplus (Sildenafil) and common over-the-counter NSAIDs like ibuprofen.

However, regulatory documents note that the concurrent use of NSAIDs may be associated with general cardiovascular risks.

Q: Is there a maximum amount of time Vigorplus is typically used for?

A: Vigorplus is officially approved for both as-needed use for one indication and as a scheduled, long-term regimen for the PAH indication. Regulatory documents do not specify a maximum duration limit for use.

Observational data on sustained use over time has been collected from extension studies.

Q: Does the time of day matter when someone is using Vigorplus?

A: The time of day is relevant depending on the specific regimen. The long-term PAH regimen requires doses to be spaced approximately 4 to 6 hours apart and taken three times a day.

For the as-needed regimen, the drug is taken prior to activity, with the timing constraint relative to the activity rather than the time of day.

Q: Is it common for people to need a dosage adjustment after starting Vigorplus?

A: Yes, official regulatory protocols formally permit the starting dose to be adjusted up or down.

This process is based on the patient’s individual tolerability and the observed effectiveness of the medicine, indicating adjustments are a formal part of the treatment protocol for the as-needed regimen.

Q: What is the difference between a contraindication and a warning for Vigorplus?

A: These are distinct classifications used in regulatory documents to communicate risk. A contraindication means the medicine must not be used at all under specific conditions (like using nitrates).

A warning advises caution or a need for specific monitoring due to a potential risk that may occur but where use may still be possible under specific management.

Q: Is Vigorplus known to cause changes in mood or sleep patterns?

A: Regulatory documents address effects on the central nervous system (CNS). Official reports from clinical trials include side effects that could impact these areas, such as insomnia (difficulty sleeping), anxiety, and depression as documented in the adverse events sections.

Q: Do any official warnings mention the use of Vigorplus in combination with alcohol?

A: Official warnings note that Sildenafil can cause blood pressure lowering effects. Combining Vigorplus with alcohol (ethanol) may increase this hypotensive effect, potentially resulting in symptoms such as dizziness or headache.

Q: Can Vigorplus affect blood sugar levels?

A: Official adverse reaction reports include rare mentions of disturbances in blood sugar regulation. These include reports of both hyperglycemia (high blood sugar) and hypoglycemic reactions (low blood sugar), though these events are considered infrequent in regulatory documentation.

Q: Is Vigorplus used to prevent symptoms, or only to treat them?

A: The drug's classification in the official Indications and Usage section describes its role as a treatment for existing conditions.

This includes managing the manifestations of pulmonary arterial hypertension (PAH) and treating vascular erection impairment, rather than being classified solely as a preventative medicine.

Q: What is the significance of the black box warning on Vigorplus?

A: The product containing Sildenafil that is used for PAH carries an FDA Boxed Warning. This warning highlights safety information from a pediatric study where high doses were associated with an increased risk of mortality.

Boxed Warnings are the FDA's most serious type of warning on drug labeling.

Q: What is the purpose of the initial testing phase for Vigorplus use?

A: The regulatory protocol describes the initial starting dose as part of a formal titration process.

This allows for dose adjustment to achieve an optimal balance between the drug’s effectiveness and its tolerability.

Q: Does Vigorplus have an effect on a person's ability to drive?

A: Due to reported side effects such as dizziness and changes in vision, official regulatory guidance advises caution.

Regulatory guidance indicates that driving or operating machinery may be avoided if these side effects are experienced.

Q: Does regulatory information mention Vigorplus causing weight change?

A: Official adverse reaction reports from clinical trials include infrequent mentions of metabolic changes. These include reports of increased weight and fluid retention as documented side effects.

Q: What is the risk of dependence or addiction described in relation to Vigorplus?

A: Official regulatory sources do not list the drug as physically addictive and no physical withdrawal symptoms are described. It is not classified as a controlled substance.

Q: Can Vigorplus interact with caffeine consumption?

A: Official drug interaction data does not typically show a direct interaction between Vigorplus and caffeine consumption. However, high caffeine intake may cause side effects like palpitations which could intensify the cardiovascular side effects of Vigorplus.

Q: Do studies suggest Vigorplus is more effective for certain age groups?

A: Clinical trials for Sildenafil included studies on various adult patient subgroups. Research findings indicated that the observed response pattern may differ in men with certain underlying conditions, such as diabetes or those who have undergone prostatectomy.

Q: Does Vigorplus interact with herbal supplements like St. John's Wort?

A: Vigorplus clearance is mediated by the CYP3A4 enzyme. Due to this mechanism, supplements known to induce CYP3A4 activity, such as St. John's Wort, could theoretically reduce the exposure of Vigorplus in the body.

Q: Can Vigorplus be used by children, based on regulatory approvals?

A: Regulatory approvals vary based on the indication. Vigorplus is not indicated for treating ED in individuals under 18 years of age.

However, the PAH formulation is approved and has official dosing protocols specifically for pediatric patients based on their body weight.

Q: What does it mean if Vigorplus has a high rate of discontinuation in trials?

A: Published clinical data indicates that the overall discontinuation rate for Sildenafil in trials is generally low.

Reports show that the discontinuation rate due to adverse events (side effects) in clinical trials is generally low.

How to Store and Dispose of Vigorplus?

This medication must be stored according to regulatory requirements to maintain its stability and effectiveness.

---

Storage Requirements

• Temperature: Store tablets at controlled room temperature, typically 25 C (77 F), with permitted excursions between 15 C and 30 C.
• Protection: The product must be protected from moisture and kept in its original, tightly closed container.
• Liquid Suspension: The reconstituted oral suspension has an official shelf-life of 60 days and must not be frozen.
• Child Safety: It is mandatory to keep Vigorplus out of the reach and sight of children.

---

Disposal Instructions

Expired or unused Vigorplus must be disposed of properly. Do not dispose of the medication via wastewater or household waste. The unused product must be discarded in accordance with local regulatory requirements or through an authorized drug take-back program.